Ryan Sun, Ph.D.

Department of Biostatistics, Division of Discovery Science

About Dr. Ryan Sun

For more information and software downloads, please see Dr. Sun's personal website https://ryanrsun.github.io.

Primary Appointment

Associate Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Adjunct Assistant Professor, Statistics, Rice University, Houston, Texas

Education & Training

Degree-Granting Education

2017	Harvard University, Boston, Massachusetts, US, Ph.D. in Biostatistics
2014	Harvard University, Boston, Massachusetts, US, MA in Biostatistics
2012	Columbia University, New York, New York, US, BS in Applied Mathematics

Postgraduate Training

2017-2019

Research Fellowship, Harvard University, Boston, Massachusetts

Experience & Service

Faculty Academic Appointments

Assistant Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2025

Administrative Appointments/Responsibilities

Course Director, GS 1023 (Survival Analysis), The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present

Other Professional Positions

Advisory Board, Boehringer Ingelheim, 2021 - 2022

Consultant, Blue Null Consulting Group, 2019 - Present

Extramural Institutional Committee Activities

Member, GSBS Curriculum Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, MD Anderson GSBS Admissions Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2023

Member, Multidisciplinary Research Program Biostatistics Review Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2022

Member, Department of Biostatistics Visiting Guest Lecturer Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, ARTEMIS Breast Cancer Trial Resource Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023

Member, Breast Cancer Moonshot Steering Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Member, Scientific Review Committee 4, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, GSBS Curriculum Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2021

Member, Lymphoma/Myeloma Immune Effector Cell Steering Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Biostatistics Protocol Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2021

Member, GSBS Biostatistics Admissions Subcommittee, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Member, Young Faculty Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Editorial Activities

Member of Editorial Board, Scientific Reports, 2023 - Present

Member of Editorial Board, Statistics in Biosciences, 2023 - Present

Honors & Awards

2018	New Researchers Conference Travel Award, Institute of Mathematical Statistics
2017	Distinguished Student Paper Award, Eastern North Atlantic Region of the International Biometric Society (ENAR)
2017	Postdoctoral Travel Award, Harvard Program in Quantitative Genomics
2014 - 2015	Distinction in Teaching Award, Harvard University
2013	Cyprus Travel Grant, Harvard-Cyprus Program
2008 - 2012	Lauren P. Breakiron Scholar, Columbia University

Professional Memberships

International Chinese Statistical Association

2020 - Present

American Statistical Association

2017 - Present

American Society of Human Genetics

2017 - Present

Selected Presentations & Talks

Local Presentations

2022. Conditionally symmetric multidimensional gaussian mixtures for testing composite null hypotheses in genetic association studies. Invited. CRC Integromics Group. Houston, Texas, US.
2021. Projecting omic data into clinical studies: vignettes from statistical analysis of ctDNA, germline, tumor sequencing, and similar data. Invited. University of Texas MD Anderson Data Science & Modeling Forum. Houston, Texas, US.
2018. A unified framework for composite null inference in mediation, pleiotropy, and replicability analyses related to genetic association studies. Invited. Program in Genetic Epidemiology and Statistical Genetics Seminar. Boston, Massachusetts, US.
2017. A unified framework for composite null inference in mediation, pleiotropy, and replicability analyses related to genetic association studies. Invited. Harvard T.H. Chan School of Public Health P01 Environmental Statistics Retreat. Boston, Massachusetts, US.
2016. Pathway analysis and gene-based inference in genomic data with the Generalized Berk-Jones statistic. Poster. Harvard T.H. Chan School of Public Health Program in Quantitative Genomics Conference. Boston, Massachusetts, US.
2016. Pathway analysis and gene-based inference in genomic data with the Generalized Berk-Jones statistic. Invited. Harvard T.H. Chan School of Public Health P01 Environmental Statistics Retreat, US.
2016. Testing for gene-environment interaction under misspecification of the environment. Invited. Program in Genetic Epidemiology and Statistical Genetics Seminar, US.

Regional Presentations

2021. Strategies for Performing Set-Based Inference in Modern Genetics Studies. Invited. Biostatistics Department Seminar, UTHealth School of Public Health. Houston, Texas, US.
2020. Set-based inference for analysis of genetic compendiums. Invited. Human Genetics Center Seminar. Houston, Texas, US.
2017. The role of inflammation pathways in lung cancer and coronary artery disease. Invited. Broad Institute Statistical Genetics Meeting. Boston, Massachusetts, US.
2017. Set-based tests using the Generalized Berk-Jones statistic in genetic association studies. Invited. Channing Division of Network Medicine Statistical Genetics and Networks Science Meeting, US.
2017. Set-based tests using the Generalized Berk-Jones statistic in genetic association studies. Invited. Broad Institute Statistical Genetics Meeting. Boston, Massachusetts, US.

National Presentations

2025. Interpretable large-scale testing of composite null hypotheses for translational genetics studies in modern biobanks. Invited. Joint Statistical Meetings 2025. Nashville, Tennessee, US.
2025. Interpretable large-scale testing of composite null hypotheses for translational genetics studies in modern biobanks. Invited. Department of Mathematics and Statistical Sciences Seminar. Milwaukee, Wisconsin, US.
2024. Interpretable large-scale testing of composite null hypotheses for translational genetics studies in modern biobanks. Invited. The 9th Workshop on Biostatistics & Bioinformatics. Atlanta, Georgia, US.
2024. Interpretable large-scale testing of composite null hypotheses for translational genetics studies in modern biobanks. Invited. University of Maryland Biostatistics & Epidemiology Seminar. College Park, Maryland, US.
2024. Interpretable large-scale testing of composite null hypotheses for translational genetics studies in modern biobanks. Invited. Georgetown University Medical Center Bio3 Seminar. Washington DC, Washington DC, US.
2024. Interpretable large-scale testing of composite null hypotheses for translational genetics studies in modern biobanks. Invited. OHSU Biostatistics Seminar. Portland, Oregon, US.
2023. Large-scale inference for composite null hypotheses in genetic association studies. Invited. Texas A&M Department of Statistics Colloquium. College Station, Texas, US.
2022. Conditionally symmetric multidimensional gaussian mixtures for testing composite null hypotheses in genetic association studies. Invited. Columbia University Department of Biostatistics Seminar. New York, New York, US.
2021. Strategies for Performing Set-Based Inference in Modern Genetics Studies. Invited. University of Nebraska Medical Center Biostatistics Seminar. (Zoom due to COVID), (Zoom due to COVID).
2021. Inference for Set-Based Effects in Genetic Association Studies with Interval-Censored Outcomes. Invited. Inference for Set-Based Effects in Genetic Association Studies with Interval-Censored Outcomes. (Zoom due to COVID), (Zoom due to COVID), US.
2021. Inference for Set-Based Effects in Genetic Association Studies with Interval-Censored Outcomes. Inference for Set-Based Effects in Genetic Association Studies with Interval-Censored Outcomes. (Zoom due to COVID), (Zoom due to COVID), US.
2020. Set-based inference for analysis of genetic compendiums (cancelled due to COVID). Invited. Set-based inference for analysis of genetic compendiums (cancelled due to COVID). (Cancelled due to COVID), (Cancelled due to COVID), US.
2020. Set-based inference for analysis of genetic compendiums (cancelled due to COVID). Invited. Set-based inference for analysis of genetic compendiums (cancelled due to COVID). (Cancelled due to COVID), (Cancelled due to COVID), US.
2019. Set-based inference for integrative analysis of genetic compendiums. Invited. University of Illinois Statistics Department Seminar. Champaign, Illinois, US.
2019. Set-based inference for integrative analysis of genetic compendiums. Invited. Florida State Statistics Department Seminar. Tallahassee, Florida, US.
2019. Set-based inference for integrative analysis of genetic compendiums. Invited. Rutgers University Biostatistics Seminar. New Brunswick, New Jersey, US.
2019. Set-based inference for integrative analysis of genetic compendiums. Invited. University of South Carolina Statistics Department Seminar. Columbia, South Carolina, US.
2019. Set-based inference for integrative analysis of genetic compendiums. Invited. Vanderbilt University Biostatistics Department Seminar. Nashville, Tennessee, US.
2019. Set-based inference for integrative analysis of genetic compendiums. Invited. University of Colorado Biostatistics Seminar. Denver, Colorado, US.
2019. Set-based inference for integrative analysis of genetic compendiums. Invited. University of Indiana Biostatistics Seminar. Indianapolis, Indiana, US.
2018. Set-based inference for integrative analysis of genetic compendiums. Invited. MD Anderson Biostatistics Department Seminar. Houston, Texas, US.
2018. Set-based inference for integrative analysis of genetic compendiums. Invited. Wake Forest Statistics Department Seminar. Winston-Salem, North Carolina, US.
2017. Set-based tests using the Generalized Berk-Jones statistic in genetic association studies. Joint Statistical Meetings (JSM). Baltimore, Maryland, US.
2017. Methods for high-dimensional inference in genetic association studies. Invited. University of New Hampshire Statistics Graduate Seminar. Durham, New Hampshire, US.
2017. Set-based tests using the Generalized Berk-Jones statistic in genetic association studies. Eastern North American Region (ENAR) of the International Biometric Society Conference. Atlanta, Georgia, US.
2016. The Generalized Berk-Jones statistic for SNP-set tests in genetic association studies. Eastern North American Region (ENAR) of the International Biometric Society Conference. Austin, Texas, US.
2015. Testing for gene-environment interaction under misspecification of the environment. Poster. Superfund Research Program Conference. San Juan, Puerto Rico, US.
2015. Testing for gene-environment interaction under misspecification of the environment. Joint Statistical Meetings (JSM). Seattle, Washington, US.

International Presentations

2024. Interpretable large-scale testing of composite null hypotheses for translational genetics studies in modern biobanks. Invited. Mediation Days. Montreal, CA.
2023. Bayesian variable selection for interval-censored outcomes in genetic association studies. Invited. CMStatistics 2023. Berlin (Talk delivered on Zoom due to hybrid format), DE.
2023. Differences in set-based tests for sparse alternatives when testing sets of outcomes compared to sets of explanatory factors in genetic association studies. Invited. Joint Statistical Meetings (JSM). Toronto, CA.
2022. Conditionally symmetric multidimensional gaussian mixtures for testing composite null hypotheses in genetic association studies. Invited. Southwestern University of Finance and Engineering Statistics Department Seminar. Chengdu (Talk delivered on zoom due to COVID), CN.
2022. Strategies for Performing Set-Based Inference in Modern Genetics Studies. Invited. University of Toronto Statistics Department Seminar. Toronto (Talk delivered on zoom), CA.
2020. Set-based inference for analysis of genetic compendiums. Invited. Statistics Department Seminar, University of Haifa. Haifa (Talk delivered on zoom due to COVID), IL.
2018. A unified framework for inference in mediation, pleiotropy, and replicability analyses related to genetic association studies. Joint Statistical Meetings (JSM). Vancouver, CA.
2018. Set-based tests using the Generalized Berk-Jones statistic in genetic association studies. Invited. Jilin University School of Mathematics Statistics Colloquium. Changchun, CN.
2015. Testing for gene-environment interaction under misspecification of the environment. International Chinese Statistical Association (ICSA) Conference. Calgary, CA.

Less

Grant & Contract Support

Date:	2026 - 2031
Title:	MD Anderson Cancer Center SPORE in Gastrointestinal Cancer
Funding Source:	NCI
Role:	Co Director
ID:	#TBA

Date:	2026 - 2031
Title:	Assessing the Immune Response to Neoantigen Exposure in Lynch Syndrome
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2026 - 2028
Title:	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Funding Source:	NIH
Role:	Other Significant
ID:	#TBA

Date:	2025 - 2030
Title:	OPTIMA: Oncology Precision Trials using Individualized Model Avatars
Funding Source:	NIH
Role:	Co-Director
ID:	#TBA

Date:	2025 - 2030
Title:	Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2025 - 2026
Title:	mRNA vaccines and therapeutic radiation for non-small cell lung cancer
Funding Source:	AMERICAN SOC FOR RADIATION ONC (ASTRO)
Role:	Other significant contributor
ID:	#TBA

Date:	2025 - 2030
Title:	Define driver biology that will lead to effective biomarker-guided therapies for 9p21-loss cancers
Funding Source:	NIH/NCI
Role:	Core 1 Biostatistics Core Lead
ID:	#TBA

Date:	2025 - 2030
Title:	A phase II and biomarker study of targeting GHR/PD-L1/CTLA-4 in unresectable hepatocellular carcinoma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	#TBA

Date:	2025 - 2029
Title:	Selvigaltin, an oral galectin-3 inhibitor, plus atezolizumab and bevacizumab, as first-line therapy in patients with unresectable hepatocellular carcinoma
Funding Source:	CANCER PREVENTION RESEARCH INST OF TX
Role:	Collaborator
ID:	RP250240

Date:	2025 - 2029
Title:	Developing A Platform for Prospective Clinical Trials Appendiceal Cancer
Funding Source:	CANCER PREVENTION RESEARCH INST OF TX
Role:	Biostatistician
ID:	RP250323

Date:	2025 - 2029
Title:	A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
Funding Source:	CANCER PREVENTION RESEARCH INST OF TX
Role:	Co-I
ID:	RP250122

Date:	2025 - 2029
Title:	Targeting ganglioside GD2 to overcome chemotherapy-resistance in triple-negative breast cancer
Funding Source:	US Department of Defense
Role:	Co-I
ID:	BC240226

Date:	2025 - 2028
Title:	Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome
Funding Source:	CANCER PREVENTION RESEARCH INST OF TX
Role:	Co-I
ID:	RP250026

Date:	2024 - 2029
Title:	Safety and efficacy of CD94-targeting CAR T cell therapy in patients with T/NK-cell malignancies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Translating molecular profiles into treatment approaches to target disparities in lymphoma
Funding Source:	Leukemia & Lymphoma Society
Role:	Co-Leader, Core A
ID:	7038-25

Date:	2024 - 2029
Title:	Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
Funding Source:	NIH/NCI
Role:	Co-Director, Core 2
ID:	1P01CA272295

Date:	2024 - 2027
Title:	Deciphering the Role of Interferon gamma Signaling in Mediating Therapeutic Resistance in Acute Myeloid Leukemia
Funding Source:	Department of Defense (DOD)
Role:	Biostatistician
ID:	#TBA

Date:	2024 - 2026
Title:	Uncovering Metabolic Rewiring of T cells in Acute Myeloid Leukemia: Spatial Considerations and Therapeutic Opportunities
Funding Source:	Department of Defense (DOD)
Role:	Biostatistician
ID:	#TBA

Date:	2024 - 2029
Title:	Development of large-scale composite null hypothesis testing approaches to perform translational genetics analyses
Funding Source:	NIH/NIGMS
Role:	PI
ID:	1R35GM154843-01

Date:	2024 - 2029
Title:	Optimizing TIL therapy and understanding tumor immune microenvironment in colorectal carcinoma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	#TBA

Date:	2024 - 2029
Title:	Integrated Clinical and Preclinical Approach for the Development of Effective Therapy in the Drug Resistant GNAS/KRAS Subtype of Appendiceal Adenocarcinoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Enhancing Macrophage Checkpoint Inhibition for the Treatment of Follicular Lymphoma
Funding Source:	Memorial Sloan Kettering Cancer Center
Role:	Co-I
ID:	#TBA

Date:	2024 - 2026
Title:	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Funding Source:	MASSACHUSETTS GENERAL HOSPITAL
Role:	Collaborator
ID:	RCTS #63766

Date:	2024 - 2025
Title:	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Funding Source:	MGH
Role:	PI
ID:	#TBA

Date:	2024 - 2028
Title:	Innovative cell therapy approaches for hematological and solid malignancies
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP240439

Date:	2024 - 2026
Title:	In Situ Generation of GD20 CAR Macrophages to Treat H3K27M Diffuse Midline Glioma
Funding Source:	AMERICAN BRAIN TUMOR ASSOCIATION
Role:	Other Significant contributor
ID:	#TBA

Date:	2024 - 2025
Title:	Understanding the interaction of mRNA vaccines and clinical responses to immune checkpoint blockade
Funding Source:	Society for Immunotherapy of Cancer
Role:	Other Significant contributor
ID:	#TBA

Date:	2024 - 2025
Title:	The Role of Human Esophageal Myofibroblasts in Barrett's Esophagus and Esophageal Adenocarcinoma
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Collaborator
ID:	#TBA

Date:	2024 - 2025
Title:	Evaluation of a novel CD79b-targeting chimeric antigen receptor T-cell therapy in patients with relapsed/refractory B-cell lymphomas
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Co-I
ID:	#TBA

Date:	2024 - 2025
Title:	Listeriolysin O Drives Innate and Adaptive Immune Responses to CD47 Immunotherapy
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Collaborator
ID:	#TBA

Date:	2024 - 2029
Title:	Advancing Precision Immuno-Oncology In Biliary Tract Cancers
Funding Source:	NIH/NCI
Role:	Core C Co-Director
ID:	#TBA

Date:	2024 - 2029
Title:	Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome
Funding Source:	NATIONAL INSTITUTES OF HEALTH
Role:	Co-I
ID:	#TBA

Date:	2024 - 2028
Title:	CD79b-targeting CAR T-cell therapy for B-cell lymphomas
Funding Source:	GATEWAY FOR CANCER RESEARCH
Role:	Co-I
ID:	9723703542

Date:	2024 - 2028
Title:	Integrative Profiling and Therapeutic Targeting of the HLA-E/CD94/NKG2A Axis to Revitalize Immune Responses in Acute Myeloid Leukemia
Funding Source:	American Cancer Society (ACS)
Role:	Collaborator
ID:	#TBA

Date:	2024 - 2027
Title:	Multimodal Spatio-Temporal Assessment of Immune Dynamics and Systemic Inflammation Associated with Venetoclax Resistance in Acute Myeloid Leukemia with Deletion 7/7q
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Biostatistician
ID:	#TBA

Date:	2024 - 2027
Title:	A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
Funding Source:	Leukemia and Lymphoma Society
Role:	Biostatistician
ID:	#TBA

Date:	2024 - 2025
Title:	Defining and Manipulating the Colorectal Cancer Microenvironment to Prevent Metastatic Relapse
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Co-I
ID:	ASCO YIA2024

Date:	2024 - 2025
Title:	Listeria-inspired phagosome escape drives STING responses to CD47 blockade
Funding Source:	American Association for Cancer Research (AACR)
Role:	Collaborator
ID:	#TBA

Date:	2024 - 2025
Title:	Restoration of LKB1 expression to sensitize non-small cell lung cancer to radiation and immunotherapy
Funding Source:	American Society for Therapeutic Radiology and Oncology (ASTRO)
Role:	Biostatistician
ID:	#TBA

Date:	2024 - 2025
Title:	Restoration of LKB1 expression to sensitize tumors to chemoradiation
Funding Source:	Radiological Society of North America (RSNA)
Role:	Biostatistician
ID:	#TBA

Date:	2024 - 2025
Title:	COVID mRNA Vaccines as Adjuvants to Immune Checkpoint Blockade
Funding Source:	INTL ASSOC FOR THE STUDY OF LUNG CANCER
Role:	Collaborator
ID:	#TBA

Date:	2024 - 2025
Title:	Restoration of LKB1 expression to sensitize non-small cell lung cancer to chemoradiation
Funding Source:	Astros Foundation Grant Program
Role:	Other Significant contributor
ID:	#TBA

Date:	2024 - 2029
Title:	Define driver biology that will lead to effective biomarker-guided therapies for 9p21-loss cancers
Funding Source:	National Cancer Institute
Role:	Core 1 Biostatistics Core Lead
ID:	P01CA288293-01

Date:	2024 - 2028
Title:	CD79b-targeting CAR T-cell therapy for B-cell lymphomas
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	#TBA

Date:	2024 - 2028
Title:	CD79b-targeting chimeric antigen receptor T-cell therapy for B-cell lymphomas
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	#TBA

Date:	2024 - 2028
Title:	EXTENDing efficacy of systemic therapy with local consolidative therapy for OligoProgressive metastatic disease (EXTEND-OP): A randomized phase II basket trial
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2023 - 2026
Title:	Gut microbiome modulation to reverse antibiotics associated dysbiosis in anti-CD19 CAR-T therapy
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	#TBA

Date:	2023 - 2028
Title:	Core 2: Remodeling the Tumor and the Immune Microenvironment to Eliminate Therapy-Resistant Triple-Negative Breast Cancers (TNBCs)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1P01CA275720-01A1

Date:	2023 - 2028
Title:	Integrated Clinical and Preclinical Approach for the Development of Effective Therapy in the Drug Resistant GNAS/KRAS Subtype of Appendiceal Adenocarcinoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA269791-01A1

Date:	2023 - 2028
Title:	Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
Funding Source:	Weill Cornell Medicine
Role:	Scientific Rigor Officer- Core 2 Co-Director
ID:	1P01CA272295-01

Date:	2023 - 2024
Title:	Recombinant IL-15, NKTR-255, to inhibit T-cell exhaustion and improve metabolic fitness of CAR T cells
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Biostatician
ID:	#TBA

Date:	2023 - 2024
Title:	Adaptive Mutability in Colorectal Cancers Treated with Epidermal Growth Factor Receptor Inhibition
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Co-I
ID:	#TBA

Date:	2023 - 2024
Title:	WRN inhibition in microsatellite instability high colorectal cancer
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Co-I
ID:	#TBA

Date:	2023 - 2024
Title:	Clinical Correlations of ctDNA in Locally Advanced Rectal Cancer
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Co-I
ID:	#TBA

Date:	2023 - 2024
Title:	Delineating the impact of clonal hematopoiesis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Co-I
ID:	#TBA

Date:	2023 - 2028
Title:	A multi-ethnic genome-wide association study with whole-exome sequencing to identify common and rare genetic risk factors for hepatocellular carcinoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA278219-01A1

Date:	2023 - 2028
Title:	Development of large-scale composite null hypothesis inference approaches to characterize translationally relevant germline genetic variants in lung cancer
Funding Source:	NIH/NCI
Role:	PD/PI
ID:	1R01CA284100-01

Date:	2023 - 2028
Title:	Tumor frameshift neoantigens mediating immunotherapy response in renal cell carcinoma
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA282063-01

Date:	2023 - 2025
Title:	Delineating the effect of clonal hematopoiesis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
Funding Source:	American Society of Hematology (ASH)
Role:	Co-I
ID:	#TBA

Date:	2023 - 2025
Title:	Racial genetic mutations disparities effect on colorectal cancer outcomes
Funding Source:	American Association for Cancer Research (AACR)
Role:	Other Significant Contributor
ID:	#TBA

Date:	2023 - 2025
Title:	Understanding KRAS Allele Specific Outcomes in Pancreatic Cancer
Funding Source:	Pancreatic Cancer Action
Role:	Co-Mentor
ID:	#TBA

Date:	2023 - 2024
Title:	Listeriolysin O Drives STING Responses to Phagocytosis Checkpoint Blockade
Funding Source:	Conquer Cancer Foundation
Role:	Collaborator
ID:	#TBA

Date:	2023 - 2024
Title:	Listeriolysin O Drives STING Signaling for Systemic Responses to Radiotherapy
Funding Source:	American Society for Therapeutic Radiology and Oncology (ASTRO)
Role:	Other Significant Contributor
ID:	#TBA

Date:	2023 - 2024
Title:	Listeriolysin O Enhances Radiation Responses to Phagocytosis Checkpoint Blockade
Funding Source:	Radiological Society of North America (RSNA)
Role:	Mentor
ID:	#TBA

Date:	2023 - 2028
Title:	Phosphorylation and Dephosphorylation at Vimentin S56 Dictate Cancer Stemness and Metastasis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2023 - 2028
Title:	Gut Microbiome Modulation to Reverse Antimicrobial Associated Dysbiosis in CAR T Cell Therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA279331-01

Date:	2023 - 2025
Title:	Development of Large-Scale Hypothesis Testing Methods for Performing Genetic Meditation Analysis
Funding Source:	MD Anderson Cancer Center
Role:	PD/PI
ID:	Andrew Sabin Family Foundation Fellowship Award

Date:	2023 - 2027
Title:	Gut Microbiome Modulation to Reverse Antimicrobial Associated Dysbiosis in CAR T Cell Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	#TBA

Date:	2023 - 2026
Title:	CD79b-targeting CAR T-cell therapy for transformed follicular lymphoma
Funding Source:	Lymphoma Research Foundation
Role:	Co-I
ID:	#TBA

Date:	2022 - 2027
Title:	System Biology Approach to Elucidate the Reprogramming of the Immune Tumor Microenvironment by Epithelial-Mesenchymal Plasticity
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1U01CA264577-01A1

Date:	2022 - 2027
Title:	Remodeling the Tumor and the Immune Microenvironment to Eliminate Therapy-Resistant Triple-Negative Breast Cancers (TNBCs)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1P01CA275720-01

Date:	2022 - 2024
Title:	Targeted monoclonal antibody to DKK3 for the treatment of pancreatic cancer
Funding Source:	Subaward via Stellanova Therapeutics, Inc
Role:	Biostatistician
ID:	#TBA

Date:	2022 - 2027
Title:	Tumor cell lineage state diversity and composition in gastric cancer progression and therapy resistance
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA266280-01A1

Date:	2022 - 2027
Title:	BAF complex deregulation in lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA266279-01A1

Date:	2022 - 2027
Title:	Vimentin phospho-malleability is critical for maintaining stemness and metastatic properties
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA262106-01A1

Date:	2022 - 2027
Title:	Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA266280-01

Date:	2022 - 2025
Title:	Developing Appendix Cancer Specific Chemotherapy: A Molecular & Clinical Approach
Funding Source:	Conquer Cancer Foundation
Role:	Biostatistician
ID:	#TBA

Date:	2022 - 2024
Title:	ASH MHFA
Funding Source:	American Society of Hematology (ASH)
Role:	Co-I
ID:	#TBA

Date:	2022 - 2023
Title:	Tracking Alloreactive T-cells to Improve Efficacy of Allogeneic CAR T-cell Therapy
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2022 - 2023
Title:	CD38 as a Targetable Antigen in Large B Cell Lymphoma (LBCL) to improve the efficacy CD19 Directed Chimeric Antigen Receptor T (CAR T) Cell Therapy and Mitigate CD19 Negative Relapse
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2022 - 2023
Title:	Targeting aggressive NK-cell leukemia and other CD94-expressing NK/T-cell lymphoproliferative disorders with CAR T-cell therapy
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	FP00014940

Date:	2022 - 2027
Title:	Multiple Myeloma in the Hispanic Population: Susceptibility, Clinical Features, and Somatic Profiles
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA272618-01

Date:	2022 - 2027
Title:	Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
Funding Source:	Weill Cornell Medicine
Role:	Core 3 Co-director
ID:	#TBA

Date:	2022 - 2025
Title:	A De-escalation protocol using Carboplatin and Paclitaxel in stage 1 triple negative breast cancer
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2022 - 2023
Title:	Adaptive Mutability in Colorectal Cancers Treated with Epidermal Growth Factor Receptor Inhibition
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2022 - 2023
Title:	Prediction of Treatment Failure Following CD19 CAR T-cell Therapy in Large B-Cell Lymphoma by Measurement of Circulating Tumor DNA
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2022 - 2025
Title:	Consensus Molecular Subtyping Assay as a Predictor of Response to Neoadjuvant Therapy in Rectal Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1UH3CA272526-01

Date:	2022 - 2027
Title:	Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2R01CA201380-06A1

Date:	2022 - 2027
Title:	Overcoming adaptive resistance to KRAS inhibition in CRC
Funding Source:	NIH/NCI subaward via Massachusetts General Hospital
Role:	Co-I
ID:	1R01CA262805-01A1

Date:	2022 - 2027
Title:	Systematic and functional analysis of tumor-host-microbiome complex interactions during metastasis formation in pancreatic cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1U54CA269135-01

Date:	2022 - 2027
Title:	Therapeutic approaches for TGF-beta-enriched minimal residual disease in patients with colorectal cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA270037-01

Date:	2022 - 2027
Title:	Anti-CD79b Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2022 - 2024
Title:	Development of DKK3-Targeted Therapeutic Antibodies for Cancer
Funding Source:	Stellanova Therapeutics, Inc
Role:	Co-I
ID:	#TBA

Date:	2022 - 2028
Title:	BC210331: Role of DKK3 in Triple Negative Breast Cancer Tumor Progression and Resistance to Therapy
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	W81XWH2210097

Date:	2022 - 2026
Title:	Targeting SMARCA4 Mutations in Pediatric Burkitt Lymphoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP220208

Date:	2022 - 2025
Title:	Therapeutic approaches for TGF-beta-enriched minimal residual disease in patients with colorectal cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP220416

Date:	2022 - 2027
Title:	Targeting the Metabolic and Immune Vulnerabilities of the Dormant Breast Cancer Stem Cell Niche
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1U54CA269128-01

Date:	2022 - 2026
Title:	A Phase I/II Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients with Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2022 - 2025
Title:	Immune features associated with outcome following CD19 CAR T-cell therapy in follicular lymphoma
Funding Source:	Lymphoma Research Foundation
Role:	Co-I
ID:	#TBA

Date:	2022 - 2025
Title:	Targeting Cyclin Dependent Kinase 9 as an Enhancer of Tumor Immunity and a Regulator of PD-L1 in Gastric Adenocarcinoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2022 - 2025
Title:	Targeting adaptive and acquired resistance to direct KRAS inhibition
Funding Source:	Massachusetts General Hospital
Role:	Bioinformatics/Statistics
ID:	FP00014745

Date:	2021 - 2026
Title:	A study of dual VEGF/PD-L1 blockade and liver SBRT in locally advanced, unresectable HCC
Funding Source:	Massachusetts General Hospital
Role:	Biostatistician
ID:	#TBA

Date:	2021 - 2022
Title:	Breast Cancer Moonshot Project 2
Funding Source:	MDACC Moonshots Program
Role:	Biostatistician
ID:	710499-80-123093-21

Date:	2021 - 2026
Title:	BAF complex deregulation in lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA266279-01

Date:	2021 - 2026
Title:	Investigating the role of Deltex1 (DTX1) regulatory element mutations in Diffuse Large B-cell Lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA266188-01

Date:	2021 - 2026
Title:	Remodeling the Tumor and the Immune Microenvironment to Impact Chemoresistant Triple-Negative Breast Cancers (TNBCs)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1P01CA257916-01A1

Date:	2021 - 2024
Title:	The MD Anderson CLEAR Program: CLinical trial Equity, Access, and Reimbursement
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Biostatistics
ID:	#TBA

Date:	2021 - 2023
Title:	Implementation of a Geriatric Care Survivorship Intervention in Older Adults who have Completed Curative Intent Therapy for Early-Stage Breast Cancer
Funding Source:	MDACC Survivorship IRG
Role:	Biostatistician
ID:	#TBA

Date:	2021 - 2026
Title:	MD Anderson Lymphoma SPORE: Improving Outcomes for Lymphoma
Funding Source:	NIH/NCI
Role:	Core Co-Director
ID:	1P50CA257882-01

Date:	2021 - 2026
Title:	Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2R01CA201380-06

Date:	2021 - 2026
Title:	Overcoming adaptive resistance to KRAS inhibition in CRC
Funding Source:	Massachusetts General Hospital
Role:	Co-I
ID:	#TBA

Date:	2021 - 2026
Title:	Vimentin phospho-malleability is critical for maintaining stemness and metastatic properties
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA262106-01

Date:	2021 - 2026
Title:	Refining and personalizing HER2-directed therapies in metastatic colorectal cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA261982-01

Date:	2021 - 2024
Title:	Integration of dental conditions in public genetic compendiums with data infrastructure development and in vitro follow-up
Funding Source:	NIH/NIDCR
Role:	PD/PI
ID:	1R01DE030898-01

Date:	2021 - 2024
Title:	The microbiota-immune axis and response to neoadjuvant chemo(immuno)therapy in triple-negative breast cancer
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2021 - 2022
Title:	Targeting HER3 Expression in Colorectal Cancer
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2021 - 2022
Title:	Prediction of Treatment Failure Following CD19 CAR T-cell Therapy in Large B-Cell Lymphoma by Measurement of Circulating Tumor DNA
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2021 - 2026
Title:	Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody
Funding Source:	NIH/NINDS
Role:	Biostatistician
ID:	5R01NS117828-02

Date:	2021 - 2023
Title:	Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R21CA259694-02

Date:	2021 - 2026
Title:	Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA247883-02

Date:	2021 - 2026
Title:	A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5R01CA260872-02

Date:	2021 - 2024
Title:	SIV: STRATEGIC Alliance Agreement
Funding Source:	Allogene Therapeutics
Role:	Biostatistician
ID:	59055

Date:	2021 - 2026
Title:	Remodeling the tumor and the immune microenvironment to impact chemoresistant triple-negative breast cancers (TNBCs)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1P01CA257916-01

Date:	2021 - 2026
Title:	Molecular and Imaging Biomarkers of Immunotherapy Response in Advanced Hepatocellular carcinoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA248399-01A1

Date:	2021 - 2026
Title:	Early progression following anti-CD19 CAR T-cell therapy in large B-cell lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA258304-01

Date:	2021 - 2025
Title:	Multi-ancestry study of sex disparity in genetic predisposition to lung cancer
Funding Source:	NIH/NCI subaward via Baylor College of Medicine
Role:	PD/PI
ID:	#TBA

Date:	2021 - 2024
Title:	PQ1 Elucidating Molecular Etiology and Biology of Young-Onset Rectal Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA258088-01

Date:	2021 - 2024
Title:	STRATEGIC ALLIANCE Rescuing CD19 CAR T-cell therapy in DLBCL
Funding Source:	Sanofi Pharmaceuticals
Role:	Co-I
ID:	57754

Date:	2021 - 2023
Title:	The microbiota-immune axis and response to neoadjuvant chemo(immuno)therapy in triple-negative breast cancer
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	AWD00005359

Date:	2020 - 2025
Title:	Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA240839-03

Date:	2020 - 2025
Title:	Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody
Funding Source:	NIH/NINDS subaward via Un of Tx Southwestern Med Ctr - Dallas
Role:	Biostatistician
ID:	1R01NS117828-01

Date:	2020 - 2023
Title:	BC200470: Optimization of Strategies that Target the PI3K/Akt/mTOR (PAM) Pathway in Triple Negative Breast Cancer (TNBC)
Funding Source:	US Department of Defense
Role:	Co-I
ID:	BC200470

Date:	2020 - 2028
Title:	Minimal Residual Disease Assessment in Colorectal Cancer
Funding Source:	Guardant Health Inc
Role:	Biostatistician
ID:	PA18-1171

Date:	2020 - 2022
Title:	MD Anderson Oropharynx Program - Biostatistics and Data Integration
Funding Source:	Stiefel Research Fund
Role:	Biostatistician
ID:	600567-80-123263-21

Date:	2020 - 2023
Title:	BC200254: Development of DKK3-Targeted Therapy for Triple Negative Breast Cancer
Funding Source:	US Department of Defense
Role:	Co-I
ID:	BC200254

Date:	2020 - 2027
Title:	STRATEGIC Alliance Agreement(SIV)
Funding Source:	Kite Pharma, Inc
Role:	Biostatistician
ID:	RCTS#58779

Date:	2020 - 2021
Title:	Validation of biomarkers of autophagic flux in patients with RAS mutant tumors
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	FP00009210

Date:	2020 - 2025
Title:	Development of Statistical Methodology to Identify Functional Risk Variants in Whole Genome Sequencing Studies with Interval-censored Outcomes
Funding Source:	NIH/NHGRI
Role:	PD/PI
ID:	1 R01 HG011381-01

Date:	2020 - 2025
Title:	PPARD Overexpression in Gastric Progenitor Cells Modulates Immunity to Accelerate Carcinogenesis
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA251949-01

Date:	2020 - 2025
Title:	A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA254351-01

Date:	2020 - 2021
Title:	Developing patient selection strategies for chemotherapy de-escalation in early-stage triple-negative breast cancer
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2020 - 2021
Title:	LAB study PRPA 6157280
Funding Source:	Amgen, Inc
Role:	Biostatistician
ID:	AWD00004909

Date:	2020 - 2024
Title:	Innovative Statistical Analysis for Genome-Wide Data with General Interval-Censored Outcomes of Oral Health in Childhood Cancer Survivors
Funding Source:	NIH/NIDCR
Role:	PI
ID:	7R03DE029238-03

Date:	2020 - 2025
Title:	Circulating Tumor DNA-Defined Minimal Residual Disease in Colorectal Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Statistician
ID:	RP200356

Date:	2020 - 2022
Title:	Microsimulation Modeling to Evaluate the Clinical Effectiveness of Novel Cancer Therapies
Funding Source:	Burroughs Wellcome Fund
Role:	Co-I
ID:	1016433.01

Date:	2020 - 2022
Title:	Development of DKK3-Targeted Therapy to Overcome Treatment Resistance in Triple Negative Breast Cancer
Funding Source:	Emerson Collective
Role:	Biostatician
ID:	#TBA

Date:	2020 - 2023
Title:	BC191486: Therapeutic Targeting of Dikkopf 3 (DKK3) for Triple Negative Breast Cancer
Funding Source:	US Department of Defense
Role:	Co-I
ID:	BC191486

Date:	2019 - 2021
Title:	Breast Cancer Moon Shot
Funding Source:	The University of Texas MD Anderson Cancer Center Moonshot Program
Role:	Biostatistician
ID:	710499-80-116858-21 (0.12CM) and 710499-80-123093-21 (1.2 CM)

Date:	2019 - 2025
Title:	Recruitment of Established Investigators
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RR190079

Date:	2019 - 2025
Title:	MD Anderson Cancer Center SPORE in Gastrointestinal Cancer
Funding Source:	NIH/NCI
Role:	Core Co-Director
ID:	5P50CA221707-04

Date:	2019 - 2026
Title:	Cancer Center Support Grant - Biostatistics Resource Group (BRG)
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	P30CA016672 - 47

Date:	2018 - 2024
Title:	Colorectal Cancer Molecular Subtype Assay Development and Validation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5UH3CA207101-04

Date:	2018 - 2023
Title:	MIRA Project 4 - Overcoming PARP inhibitor resistance in patients with breast cancer who have germline BRCA mutations
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP180813

Date:	2018 - 2020
Title:	Paracrine Role of Endothelial Cells in HER3-Mediated Colon Cancer Cell Survival
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	W81XWH1810405

Date:	2018 - 2023
Title:	Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA218230-05

Date:	2018 - 2024
Title:	Activating p53 for colorectal cancer prevention
Funding Source:	NIH/NCI
Role:	Statistician
ID:	5R01CA214954-05

Date:	2016 - 2021
Title:	Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	5R01CA201380-05

Date:	2016 - 2022
Title:	Novel signaling pathways regulating pancreatic cancer pathogenesis
Funding Source:	NIH/NCI
Role:	Statistician
ID:	5R01CA196941-05

Date:	1983 - 2019
Title:	Environmental health statistics training grant in biostatistics
Funding Source:	NIH/NIEHS
Role:	Trainee
ID:	5T32ES007142-37

Date:	1979 - 2017
Title:	Biometry/epidemiology training grant in biostatistics
Funding Source:	NIH/NCI
Role:	Trainee
ID:	5T32CA009337-32

Title:	Title: Training Program in Biostatistics for Cancer Research
Funding Source:	Rice University
Role:	CO-Director
ID:	#TBA

Selected Publications

Peer-Reviewed Articles

Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature, 2025. e-Pub 2025. PMID: 41125896.
Li, X, Singhal, K, Deng, Q, Chihara, D, Russler-Germain, D, Harkins, RA, Henderson, J, Arita, K, Kizhakeyil, A, Sun, R, Lakra, P, Hussein, UK, Foltz, JA, Wilson, A, Schmidt, E, Nizamuddin, I, Dinh, T, Kesaraju, A, Hamilton, MP, Allen, CE, Gandhi, MK, Tobin, J, Jiang, A, Hilton, L, Scott, DW, Vega Vazquez, F, Flowers, CR, Westin, JR, Griffith, OL, Fehniger, TA, Griffith, M, Green, M. Large B cell lymphoma microenvironment archetype profiles. Cancer Cell 43(7):1347-1364.e13, 2025. e-Pub 2025. PMID: 40920660.
Byun J, Han Y, Choi J, Sun R, Shaw VR, Zhu C, Xiao X, Lusk C, Badr H, Lee HS, Jang HJ, Li Y, Lim H, Long E, Liu Y, Kachuri L, Walsh KM, Wiencke JK, Albanes D, Lam S, Tardon A, Neuhouser ML, Barnett MJ, Chen C, Bojesen S, Brenner H, Landi MT, Johansson M, Risch A, Wichmann HE, Bickeboller H, Christiani DC, Rennert G, Arnold S, Field JK, Shete S, Le Marchand L, Liu G, Andrew AS, Zienolddiny S, Grankvist K, Johansson M, Caporaso N, Taylor F, Lazarus P, Schabath MB, Aldrich MC, Patel A, Lin X, Zanetti KA, Harris CC, Chanock S, McKay J, Schwartz AG, Hung RJ, Amos CI. Genome-wide association study for lung cancer in 6531 African Americans reveals new susceptibility loci. Hum Mol Genet 34(14):1227-1237, 2025. e-Pub 2025. PMID: 40341939.
Pellatt, AJ, Bent, AH, Hornstein, N, Parseghian, C, Huey, RW, Raghav, KS, Morris, VK, Overman, MJ, Morelli, P, Willis, JA, Le, PH, Shen, JY, Kee, BK, Eluri, M, Higbie, V, Alfaro-Munoz, KD, Aziz, KE, Kell, R, Sun, R, Kopetz, S, Dasari, NV. Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40669021.
Grippin, A, Kim, AD, Liu, Y, Copling, S, Nalin, AP, Crabtree, K, Cheng, H, Kui, N, Zhang, Z, McAleer, MF, Grosshans, DR, McGovern, SL, Sun, R, Paulino, AC. Osteoradionecrosis in Pediatric Patients Treated with Proton Therapy for Head and Neck Malignancies. International Journal of Radiation Oncology Biology Physics 122(1):159-163, 2025. e-Pub 2025. PMID: 39674326.
Li, X, Chen, H, Selvaraj, MS, Van Buren, E, Zhou, H, Wang, Y, Sun, R, McCaw, ZR, Yu, Z, Jiang, MZ, Dicorpo, D, Gaynor, SM, Dey, R, Arnett, D, Benjamin, EJ, Bis, JC, Blangero, J, Boerwinkle, E, Bowden, DW, Brody, JA, Cade, BE, Carson, A, Carlson, JC, Chami, N, Chen, YI, Curran, JE, De Vries, PS, Fornage, M, Franceschini, N, Freedman, BI, Gu, C, Heard-Costa, NL, He, J, Hou, L, Hung, YJ, Irvin, MR, Kaplan, RC, Kardia, SL, Kelly, TN, Konigsberg, I, Kooperberg, C, Kral, BG, Li, C, Li, Y, Lin, H, Liu, CT, Loos, RJ, Mahaney, MC, Martin, LW, Menon, VK. A statistical framework for multi-trait rare variant analysis in large-scale whole-genome sequencing studies. Nature Computational Science 5(2):125-143, 2025. e-Pub 2025. PMID: 39920506.
Sun, R, McCaw, ZR, Lin, X. Testing a Large Number of Composite Null Hypotheses Using Conditionally Symmetric Multidimensional Gaussian Mixtures in Genome-Wide Studies. Journal of the American Statistical Association 120(550):605-617, 2025. e-Pub 2025. PMID: 40539117.
LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO. Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma. Oncology 103(6):490-497, 2025. e-Pub 2025. PMID: 39427654.
Gorman, BR, Ji, SG, Francis, M, Sendamarai, AK, Shi, Y, Devineni, P, Saxena, U, Partan, E, DeVito, AK, Byun, J, Han, Y, Xiao, X, Sin, DD, Timens, W, Moser, J, Muralidhar, S, Ramoni, R, Hung, RJ, McKay, J, Bossé, Y, Sun, R, Amos, CI, Pyarajan, S. Multi-ancestry GWAS meta-analyses of lung cancer reveal susceptibility loci and elucidate smoking-independent genetic risk. Nature Communications 15(1), 2024. e-Pub 2024. PMID: 39366959.
Yousef, M, Yousef, A, Chowdhury, S, Fanaeian, M, Knafl, M, Peterson, J, Zeineddine, MA, Alfaro, KD, Zeineddine, F, Goldstein, D, Hornstein, N, Dasari, NV, Huey, RW, Johnson, B, Serpas Higbie, V, Bent, AH, Kee, BK, Lee, MS, Morelli, MP, Morris, VK, Halperin, DM, Overman, MJ, Parseghian, C, Vilar Sanchez, E, Wolff, RA, Raghav, KS, White, MG, Uppal, A, Sun, R, Wang, W, Kopetz, S, Willis, JA, Shen, JY. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncology 10(11), 2024. e-Pub 2024. PMID: 39264607.
Chamseddine, SM, Yavuz, BG, Mohamed, Y, Lee, SS, Yao, JC, Hu, Z, Lapelusa, M, Xiao, L, Sun, R, Morris, JS, Hatia, RI, Hassan, MM, Duda, DG, Diab, M, Mohamed, A, Nassar, A, Amin, H, Kaseb, A. Circulating Galectin-3. Journal of Immunotherapy and Precision Oncology 7(4):255-262, 2024. e-Pub 2024. PMID: 39524465.
Yam, C, Patel, MM, Hill, H, Sun, R, Bassett Jr, R, Kong, EK, Damodaran, S, Koenig, KB, Abouharb, S, Saleem, S, Bisen, AK, Murthy, RK, Ramirez, DL, Rauch, GM, Adrada, BE, Candelaria, RP, Wang, X, Mittendorf, EA, Thompson, A, White, JB, Ravenberg, EE, Clayborn, A, Ding, Q, Booser, DJ, Oke, OC, Brewster, A, Hortobagyi, GN, Ibrahim, NK, Litton, J, Valero, V, Arun, BK, Tripathy, D, Chang, J, Chen, K, Korkut, A, Moulder, S, Huo, L, Lim, B, Ueno, NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Research Communications 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
Lin TA, McCaw ZR, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Sherry AD, Noticewala SS, Fuller CD, Thomas CR, Sun R, Lee JJ, Lin R, Yuan Y, Shyr Y, Meirson T, Ludmir EB. Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clin Cancer Res 30(20):4791-4799, 2024. e-Pub 2024. PMID: 39133081.
Xu Z, Choi J, Sun R. Set-based tests for genetic association studies with interval-censored competing risks outcomes. Statistics in Biosciences, 2024. e-Pub 2024.
Antonoff, MB, Kui, N, Sun, R, Deboever, N, Hofstetter, WL, Mehran, RJ, Morris, VK, Rice, DC, Swisher, SG, Vaporciyan, AA, Walsh, GL, Rajaram, R. Factors associated with receipt of pulmonary metastasectomy in patients with lung-limited metastatic colorectal cancer. Journal of Thoracic and Cardiovascular Surgery 168(1):263-271, 2024. e-Pub 2024. PMID: 37690624.
Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80(1):87-101, 2024. e-Pub 2024. PMID: 38381705.
Choi J, Xu Z, Sun R. Variance-components tests for genetic association with multiple interval-censored outcomes. Stat Med 43(13):2560-2574, 2024. e-Pub 2024. PMID: 38636557.
Scott H, Alvarez PE, Howell RM, Riegel A, Sun R, Liu K, Kry SF. Chromatic bleaching and fractionation effects on optically stimulated luminescent dosimeter reuse. Med Phys, 2024. e-Pub 2024. PMID: 38852196.
Chamseddine, SM, Lapelusa, M, Carter, K, Nguyen, V, Mohamed, YI, Sakr, Y, Rojas Hernandez, CM, Hatia, RI, Hassan, MM, Goss, JA, Elsayes, KM, Rashid, A, Sun, R, Cao, HT, Amin, H, Kaseb, A. Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab. Journal of Gastrointestinal Oncology 15(3):1324-1330, 2024. e-Pub 2024. PMID: 38989410.
Hsu, EJ, Lin, TA, Dabush, DR, McCaw, ZR, Koong, A, Lin, C, Abi Jaoude, J, Patel, RR, Kouzy, R, El Alam, MB, Noticewala, SS, Yang, Y, Sherry, AD, Fuller, C, Thomas, CR, Tang, C, Msaouel, P, Das, P, Huang, B, Tian, L, Sun, R, Lee, JJ, Meirson, T, Ludmir, EB. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials. Journal of the National Cancer Institute 116(6):990-994, 2024. e-Pub 2024. PMID: 38331394.
Bahrambeigi, V, Lee, JJ, Branchi, V, Rajapakshe, K, Xu, Z, Kui, N, Henry, JT, Kun, W, Stephens, BM, Dhebat, S, Hurd, MW, Sun, R, Yang, P, Ruppin, E, Wang, W, Kopetz, S, Maitra, A, Guerrero, PA. Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-Specific Transcriptome and Molecular Subtype. Cancer Research 84(10):1719-1732, 2024. e-Pub 2024. PMID: 38451249.
Jallouk, AP, Kui, N, Sun, R, Westin, JR, Steiner, RE, Nair, R, Nastoupil, L, Fayad, LE, Zaki, AA, Hawkins, MC, Adkins, S, Noorani, M, Das, K, Henderson, J, Shpall, E, Kebriaei, P, Ramdial, JL, Flowers, CR, Neelapu, SS, Ahmed, S, Strati, P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2024. PMID: 38031807.
Hornstein, N, Zeineddine, MA, Gunes, BB, Pellatt, AJ, Knafl, M, Zhu, H, Willett, A, Yousef, A, Liu, S, Sun, R, Futreal, A, Woodman, SE, Taggart, MW, Overman, MJ, Halperin, DM, Raghav, KS, Shen, JY. Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Research Communications 4(5):1363-1368, 2024. e-Pub 2024. PMID: 38709066.
Li, Y, Xiao, X, Li, J, Han, Y, Cheng, C, Fernandes, GF, Slewitzke, SE, Rosenberg, SM, Zhu, M, Byun, J, Bossé, Y, McKay, J, Albanes, D, Lam, S, Tardón, A, Chen, C, Bojesen, SE, Landi, MT, Johansson, M, Risch, A, Bickeböller, H, Wichmann, He, Christiani, DC, Rennert, G, Arnold, SM, Goodman, G, Field, JK, Davies, MP, Shete, S, Le Marchand, L, Liu, G, Hung, RJ, Andrew, AS, Kiemeney, L, Sun, R, Zienolddiny, S, Grankvist, K, Johansson, M, Caporaso, N, Cox, A, Hong, YC, Lazarus, P, Schabath, MB, Aldrich, MC, Schwartz, AG, Gorlov, IP, Purrington, K, Yang, P, Liu, Y, Bailey-Wilson, J, Pinney, SM, Mandal, D, Willey, J, Gaba, C, Brennan, P, Xia, J, Shen, H, Amos, CI. Lung Cancer in Ever- and Never-Smokers. Cancer Epidemiology Biomarkers and Prevention 33(3):389-399, 2024. e-Pub 2024. PMID: 38180474.
Zhu H, Choi J, Kui N, Yang T, Wei P, Li D, Sun R. Identification of Pancreatic Cancer Germline Risk Variants With Effects That Are Modified by Smoking. JCO Precis Oncol 8:e2300355, 2024. e-Pub 2024. PMID: 38564682.
Sun R, Shi A, Lin X. Differences in set-based tests for sparse alternatives when testing sets of outcomes compared to sets of explanatory factors in genetic association studies. Biostatistics 25(1):171-187, 2024. e-Pub 2022. PMID: 36000269.
Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. e-Pub 2024. PMID: 37822075.
Zeineddine, F, Zeineddine, MA, Yousef, A, Gu, Y, Chowdhury, S, Dasari, NV, Huey, RW, Johnson, B, Kee, BK, Lee, MS, Morelli, MP, Morris, VK, Overman, MJ, Parseghian, C, Raghav, KS, Willis, JA, Wolff, RA, Kawaguchi, Y, Vauthey, JN, Sun, R, Kopetz, S, Shen, JY. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precision Oncology 7(1), 2023. e-Pub 2023. PMID: 36781990.
Chu F, Cao J, Liu J, Yang H, Davis TJ, Kuang SQ, Cheng X, Zhang Z, Karri S, Vien LT, Bover L, Sun R, Vega F, Green M, Davis RE, Neelapu SS. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. J Immunother Cancer 11(11), 2023. e-Pub 2023. PMID: 38007239.
Sherry, AD, Msaouel, P, McCaw, ZR, Abi Jaoude, J, Hsu, EJ, Kouzy, R, Patel, RR, Yang, Y, Lin, TA, Taniguchi, C, Rödel, C, Fokas, E, Tang, C, Fuller, C, Minsky, B, Meirson, T, Sun, R, Ludmir, EB. Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials. European Journal of Cancer 194, 2023. e-Pub 2023. PMID: 37827064.
Sun R, Sun D, Zhu L, Sun J. Regression analysis of general mixed recurrent event data. Lifetime Data Anal 29(4):807-822, 2023. e-Pub 2023. PMID: 37438585.
Chamseddine, SM, Mohamed, Y, Lee, SS, Yao, JC, Hu, Z, Tran Cao, HS, Xiao, L, Sun, R, Morris, J, Hatia, RI, Hassan, MM, Duda, DG, Diab, M, Mohamed, A, Nassar, A, Datar, S, Amin, H, Kaseb, A. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology (Switzerland) 101(11):730-737, 2023. e-Pub 2023. PMID: 37467732.
Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. e-Pub 2023. PMID: 37824798.
Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
Wang, H, Moniruzzaman, R, Li, L, Ji, B, Liu, Y, Zuo, X, Abbasgholizadeh, R, Zhao, J, Liu, G, Wang, R, Tang, H, Sun, R, Su, X, Tan, TH, Maitra, A, Wang, H. Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia. Journal of Clinical Investigation 133(12), 2023. e-Pub 2023. PMID: 37140994.
Sun R, Zhu L, Li Y, Yasui Y, Robison L. Inference for Set-Based Effects in Genetic Association Studies with Interval Censored Outcomes. Biometrics 79(2):1573-1585, 2023. e-Pub 2023. PMID: 35165890.
Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
McCaw ZR, Gaynor SM, Sun R, Lin X. Leveraging a surrogate outcome to improve inference on a partially missing target outcome. Biometrics 79(2):1472-1484, 2023. e-Pub 2023. PMID: 35218565.
Sohn AJ, Taherian M, Katz MHG, Prakash LR, Chatterjee D, Wang H, Kim M, Tzeng CD, Lee JE, Ikoma N, Rashid A, Wolff RA, Zhao D, Koay EJ, Sun R, Maitra A, Wang H. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Am J Surg Pathol 47(4):421-430, 2023. e-Pub 2023. PMID: 36746143.
Han Y, Byun J, Zhu C, Sun R, Roh JY, Cordell HJ, Lee HS, Shaw VR, Kang SW, Razjouyan J, Cooley MA, Hassan MM, Siminovitch KA, Folseraas T, Ellinghaus D, Bergquist A, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, Study Group IP, McGlynn KA, Roberts LR, Amos CI. Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis. Nat Commun 14(1):1069, 2023. e-Pub 2023. PMID: 36828809.
Patni T, Lee CT, Li Y, Kaste S, Zhu L, Sun R, Hudson MM, Ness KK, Neumann A, Robison LL. Factors for poor oral health in long-term childhood cancer survivors. BMC Oral Health 23(1):73, 2023. e-Pub 2023. PMID: 36739372.
Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2022. PMID: 35952327.
Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol 41(3):101200JCO2201423, 2023. e-Pub 2022. PMID: 36351210.
Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S. Acquired Genomic Alterations on First-Line Chemotherapy with Cetuximab in Advanced Colorectal Cancer. Journal of Clinical Oncology 41(3):472-478, 2023. e-Pub 2023. PMID: 36067452.
Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Padmanabhan Iyer S, Horowitz SB, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
Li, X, Quick, C, Zhou, H, Gaynor, SM, Liu, Y, Chen, H, Selvaraj, MS, Sun, R, Dey, R, Arnett, DK, Bielak, LF, Bis, JC, Blangero, J, Boerwinkle, E, Bowden, DW, Brody, JA, Cade, BE, Correa, A, Cupples, LA, Curran, JE, de Vries, PS, Duggirala, R, Freedman, BI, Göring, HH, Guo, X, Haessler, J, Kalyani, RR, Kooperberg, C, Kral, BG, Lange, LA, Manichaikul, AW, Martin, LW, McGarvey, ST, Mitchell, BD, Montasser, ME, Morrison, AC, Naseri, T, O’Connell, JR, Palmer, ND, Peyser, PA, Psaty, BM, Raffield, LM, Redline, S, Reiner, AP, Reupena, MS, Rice, K, Rich, SS, Sitlani, CM, Smith, JA, Menon, VK. Powerful, scalable and resource-efficient meta-analysis of rare variant associations in large whole genome sequencing studies. Nature Genetics 55(1):154-164, 2023. e-Pub 2023. PMID: 36564505.
Li, Z, Li, X, Zhou, H, Gaynor, SM, Selvaraj, MS, Arapoglou, T, Quick, C, Liu, Y, Chen, H, Sun, R, Dey, R, Arnett, DK, Auer, PL, Bielak, LF, Bis, JC, Blackwell, T, Blangero, J, Boerwinkle, E, Bowden, DW, Brody, JA, Cade, BE, Conomos, MP, Correa, A, Cupples, LA, Curran, JE, de Vries, PS, Duggirala, R, Franceschini, N, Freedman, BI, Göring, HH, Guo, X, Kalyani, RR, Kooperberg, C, Kral, BG, Lange, LA, Lin, BM, Manichaikul, AW, Manning, AK, Martin, LW, Mathias, R, Meigs, JB, Mitchell, BD, Montasser, ME, Morrison, AC, Naseri, T, O'connell, Jr, Palmer, ND, Peyser, PA, Psaty, BM, Raffield, LM. A framework for detecting noncoding rare-variant associations of large-scale whole-genome sequencing studies. Nature Methods 19(12):1599-1611, 2022. e-Pub 2022. PMID: 36303018.
Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
Huang B, Sun R, Claggett B, Tian L, Ludmir EB, Wei LJ. Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial. JAMA Oncol 8(10):1502-1503, 2022. e-Pub 2022. PMID: 35980612.
Li Y, Xiao X, Li J, Byun J, Cheng C, Bossé Y, McKay J, Albanes D, Lam S, Tardon A, Chen C, Bojesen SE, Landi MT, Johansson M, Risch A, Bickeböller H, Wichmann HE, Christiani DC, Rennert G, Arnold S, Goodman G, Field JK, Davies MPA, Shete SS, Le Marchand L, Melander O, Brunnström H, Liu G, Hung RJ, Andrew AS, Kiemeney LA, Shen H, Sun R, Zienolddiny S, Grankvist K, Johansson M, Caporaso N, Teare DM, Hong YC, Lazarus P, Schabath MB, Aldrich MC, Schwartz AG, Gorlov I, Purrington K, Yang P, Liu Y, Han Y, Bailey-Wilson JE, Pinney SM, Mandal D, Willey JC, Gaba C, Brennan P, Amos CI, cancer consortium IL. Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk. Hum Mol Genet 31(16):2831-2843, 2022. e-Pub 2022. PMID: 35138370.
Byun J, Han Y, Li Y, Xia J, Long E, Choi J, Xiao X, Zhu M, Zhou W, Sun R, Bossé Y, Song Z, Schwartz A, Lusk C, Rafnar T, Stefansson K, Zhang T, Zhao W, Pettit RW, Liu Y, Li X, Zhou H, Walsh KM, Gorlov I, Gorlova O, Zhu D, Rosenberg SM, Pinney S, Bailey-Wilson JE, Mandal D, de Andrade M, Gaba C, Willey JC, You M, Anderson M, Wiencke JK, Albanes D, Lam S, Tardon A, Chen C, Goodman G, Bojeson S, Brenner H, Landi MT, Chanock SJ, Johansson M, Muley T, Risch A, Wichmann HE, Bickeböller H, Christiani DC, Rennert G, Arnold S, Field JK, Shete S, Le Marchand L, Melander O, Brunnstrom H, Liu G, Andrew AS, Kiemeney LA, Shen H, Zienolddiny S, Grankvist K, Johansson M, Caporaso N, Cox A, Hong YC, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Patel A, Lan Q, Rothman N, Taylor F, Kachuri L, Witte JS, Sakoda LC, Spitz M, Brennan P, Lin X, McKay J, Hung RJ, Amos CI. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. Nat Genet 54(8):1167-1177, 2022. e-Pub 2022. PMID: 35915169.
Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
Grover P, Veilleux O, Tian L, Sun R, Previtera M, Curran E, Muffly L. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. Blood Adv 6(5):1608-1618, 2022. e-Pub 2022. PMID: 34610109.
Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
Li X, Yung G, Zhou H, Sun R, Li Z, Hou K, Zhang MJ, Liu Y, Arapoglou T, Wang C, Ionita-Laza I, Lin X. A multi-dimensional integrative scoring framework for predicting functional variants in the human genome. Am J Hum Genet 109(3):446-456, 2022. e-Pub 2022. PMID: 35216679.
Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
Alhalabi, O, Soomro, Z, Sun, R, Hasanov, E, Albittar, A, Tripathy, D, Valero, V, Ibrahim, NK. Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. npj Breast Cancer 7(1), 2021. e-Pub 2021. PMID: 33742001.
Sun R, McCaw Z, Tian L, Uno H, Hong F, Kim DH, Wei LJ. Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. J Immunother Cancer 9(11), 2021. e-Pub 2021. PMID: 34799398.
Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
Bhamidipati, D, Colina, A, Hwang, H, Wang, H, Katz, MH, Fournier, KF, Serpas Higbie, V, Thomas, J, Sun, R, Wolff, RA, Raghav, KS, Overman, MJ. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy. ESMO Open 6(3), 2021. e-Pub 2021. PMID: 33940348.
Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. e-Pub 2021. PMID: 32984932.
Sun R, Xu M, Li X, Gaynor S, Zhou H, Li Z, Bossé Y, Lam S, Tsao MS, Tardon A, Chen C, Doherty J, Goodman G, Bojesen SE, Landi MT, Johansson M, Field JK, Bickeböller H, Wichmann HE, Risch A, Rennert G, Arnold S, Wu X, Melander O, Brunnström H, Le Marchand L, Liu G, Andrew A, Duell E, Kiemeney LA, Shen H, Haugen A, Johansson M, Grankvist K, Caporaso N, Woll P, Dawn Teare M, Scelo G, Hong YC, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Albanes D, Mak R, Barbie D, Brennan P, Hung RJ, Amos CI, Christiani DC, Lin X. Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. Genet Epidemiol 45(1):99-114, 2021. e-Pub 2021. PMID: 32924180.
Kim DH, Li X, Bian S, Wei LJ, Sun R. Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia. JAMA Netw Open 4(1):e2034745, 2021. e-Pub 2021. PMID: 33507253.
Xu, M, Tapia, C, Hajjar, J, Sabir, SH, Colen, R, Nagarajan, P, Aung, PP, Gong, J, Rodon Ahnert, J, Fu, S, Stephen, B, Roy Chowdhuri, S, Le, H, Yang, V, Zarifa, A, Abdelsalam, ME, Jhingran, A, Javle, M, Pant, S, Carter, B, Milton, D, Sun, R, Karp, DD, Koay, EJ, Yang, Y, Wistuba, II, Hwu, P, Meric-Bernstam, F, Naing, A. Implementation of a novel web-based lesion selection tool to improve acquisition of tumor biopsy specimens. Journal of Immunotherapy and Precision Oncology 4(2):45-52, 2021. e-Pub 2021. PMID: 35663531.
Deng, Q, Han, G, Puebla-Osorio, N, Ma, MJ, Strati, P, Chasen, B, Dai, E, Dang, M, Jain, N, Yang, H, Wang, Y, Zhang, S, Wang, R, Chen, R, Showell, J, Ghosh, S, Patchva, S, Zhang, Q, Sun, R, Hagemeister, FB, Fayad, LE, Samaniego, F, Lee, HC, Nastoupil, L, Fowler, N, Davis, RE, Westin, JR, Neelapu, SS, Wang, L, Green, M. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
Park, HR, Sun, R, Panganiban, RA, Christiani, DC, Lu, Q. MicroRNA-124 Reduces Arsenic-induced Endoplasmic Reticulum Stress and Neurotoxicity and is Linked with Neurodevelopment in Children. Scientific reports 10(1), 2020. e-Pub 2020. PMID: 32246005.
Sun R, Wang Z, Claus Henn B, Su L, Lu Q, Lin X, Wright RO, Bellinger DC, Kile M, Mazumdar M, Tellez-Rojo MM, Schnaas L, Christiani DC. Identification of novel loci associated with infant cognitive ability. Mol Psychiatry 25(11):3010-3019, 2020. e-Pub 2020. PMID: 30120420.
Colina A, Hwang H, Wang H, Katz MHG, Sun R, Lee JE, Thomas J, Tzeng CW, Wolff RA, Raghav K, Overman MJ. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open 5(6), 2020. e-Pub 2020. PMID: 33188051.
Li X, Li Z, Zhou H, Gaynor SM, Liu Y, Chen H, Sun R, Dey R, Arnett DK, Aslibekyan S, Ballantyne CM, Bielak LF, Blangero J, Boerwinkle E, Bowden DW, Broome JG, Conomos MP, Correa A, Cupples LA, Curran JE, Freedman BI, Guo X, Hindy G, Irvin MR, Kardia SLR, Kathiresan S, Khan AT, Kooperberg CL, Laurie CC, Liu XS, Mahaney MC, Manichaikul AW, Martin LW, Mathias RA, McGarvey ST, Mitchell BD, Montasser ME, Moore JE, Morrison AC, O'Connell JR, Palmer ND, Pampana A, Peralta JM, Peyser PA, Psaty BM, Redline S, Rice KM, Rich SS, Smith JA, Tiwari HK, Tsai MY, Vasan RS, Wang FF, Weeks DE, Weng Z, Wilson JG, Yanek LR, (TOPMed) Consortium NTFPM, Working Group TL, Neale BM, Sunyaev SR, Abecasis GR, Rotter JI, Willer CJ, Peloso GM, Natarajan P, Lin X. Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. Nat Genet 52(9):969-983, 2020. e-Pub 2020. PMID: 32839606.
Zhu, L, Tong, X, Cai, D, Li, Y, Sun, R, Srivastava, DK, Hudson, MM. Maximum likelihood estimation for the proportional odds model with mixed interval-censored failure time data. Journal of Applied Statistics:1-17, 2020. e-Pub 2020. PMID: 34349336.
Sun R, Lin X. Genetic Variant Set-Based Tests Using the Generalized Berk-Jones Statistic with Application to a Genome-Wide Association Study of Breast Cancer. J Am Stat Assoc 115(531):1079-1091, 2020. e-Pub 2020. PMID: 33041403.
Gaynor SM, Sun R, Lin X, Quackenbush J. Identification of differentially expressed gene sets using the Generalized Berk-Jones statistica. Bioinformatics 35(22):4568-4576, 2019. e-Pub 2019. PMID: 31062858.
Sun R, Hui S, Bader GD, Lin X, Kraft P. Powerful gene set analysis in GWAS with the Generalized Berk-Jones statistic. PLoS Genet 15(3):e1007530, 2019. e-Pub 2019. PMID: 30875371.
Orkaby AR, Rich MW, Sun R, Lux E, Wei LJ, Kim DH. Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis. J Am Geriatr Soc 66(10):1987-1991, 2018. e-Pub 2018. PMID: 30251369.
Sun R, Carroll RJ, Christiani DC, Lin X. Testing for gene-environment interaction under exposure misspecification. Biometrics 74(2):653-662, 2018. e-Pub 2018. PMID: 29120492.
Wang Z, Claus Henn B, Wang C, Wei Y, Su L, Sun R, Chen H, Wagner PJ, Lu Q, Lin X, Wright R, Bellinger D, Kile M, Mazumdar M, Tellez-Rojo MM, Schnaas L, Christiani DC. Genome-wide gene by lead exposure interaction analysis identifies UNC5D as a candidate gene for neurodevelopment. Environ Health 16(1):81, 2017. e-Pub 2017. PMID: 28754176.
Sun R, Bouchard MB, Hillman EM. SPLASSH: Open source software for camera-based high-speed, multispectral in-vivo optical image acquisition. Biomed Opt Express 1(2):385-397, 2010. e-Pub 2010. PMID: 21258475.

Letters to the Editor

Sun, R, Seibert, TM, Wei, LJ. Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. New England Journal of Medicine 392: 1141, 2025.
Sun, R, Wei, LJ. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA 332: 1112, 2024.
Sun R, Wei LJ. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 390: 1939, 2024.
Sun R, Moraleda JM, Wei LJ. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma. JAMA Oncol 10: 674, 2024.
Sun, R, Wei, LJ. Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?. JAMA Oncology 10: 537, 2024.
Sun, R, Liu, J, Wei, LJ. Assessing Predictability of Pathologic Lymph Node Regression for Recurrence and Survival in Esophageal Adenocarcinoma. Journal of Clinical Oncology 42: 366-367, 2024.
Sun, R, Seibert, TM, Wei, LJ. Predictability of Olfactory Neuroblastoma Staging Systems. JAMA Otolaryngology - Head and Neck Surgery 150: 84-85, 2024.
Sun R, Wei LJ. Efficacy, Safety, and Analysis Issues in a Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer. JAMA Surg 158: 1357-1358, 2023.
Sun R, Huang B, Wei LJ. Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer. J Clin Oncol 41: 1952-1953, 2023.
Sun R, Wei LJ. Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 40: JCO2201084, 2022.
Sun R, Wei LJ. Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. JAMA Oncol 8: 1701, 2022.
Sun, R, Wei, LJ. Pembrolizumab in Triple-Negative Breast Cancer. New England Journal of Medicine 387: 1435-1436, 2022.
Sun R, Tian L, Wei LJ. Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma. JAMA Surg 157: 458-459, 2022.
Sun R, Messick C, Wei LJ. Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis for Low Rectal Cancers. JAMA Surg 156: 202-203, 2021.
Sun R, Kim DH, Wei LJ. Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. JAMA Oncol 6: 1121-1122, 2020.
Wei LJ, Sun R, Orkaby AR, Kim DH, Zhu H. Biodegradable-polymer stents versus durable-polymer stents. Lancet 393: 1932-1933, 2019.
Sun R, Zhu H, Wei LJ. Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer. JAMA Oncol 5: 270, 2019.
Sun R, Lee H, Wei LJ. Interpreting the Long-term Prognostic Value of Total Mesorectal Excision Plane Quality in Rectal Adenocarcinoma. JAMA Surg 154: 96, 2019.
Sun R, Wei LJ. Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma. JAMA Oncol 5: 112-113, 2019.
Sun R, Nie L, Huang B, Kim DH, Wei LJ. Quantifying Immunoscore performance. Lancet 392: 1624, 2018.
Sun R, Rich MW, Wei LJ. Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med 379: e18, 2018.
Sun R, Horiguchi M, Wei LJ. Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival. J Clin Oncol 36: 1378-1379, 2018.

Less

CV information above last modified July 22, 2026

Ryan Sun, Ph.D.

About Dr. Ryan Sun

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Ryan Sun, Ph.D.

About Dr. Ryan Sun

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson